296 related articles for article (PubMed ID: 30972278)
1. SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade.
Zhao M; Guo W; Wu Y; Yang C; Zhong L; Deng G; Zhu Y; Liu W; Gu Y; Lu Y; Kong L; Meng X; Xu Q; Sun Y
Acta Pharm Sin B; 2019 Mar; 9(2):304-315. PubMed ID: 30972278
[TBL] [Abstract][Full Text] [Related]
2. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of canine SHP2 mutants and anti-tumour effect of SHP2 inhibitor, SHP099, in a xenograft mouse model of canine histiocytic sarcoma.
Tani H; Miyamoto R; Nagashima T; Michishita M; Tamura K; Bonkobara M
Vet Comp Oncol; 2022 Mar; 20(1):109-117. PubMed ID: 34241941
[TBL] [Abstract][Full Text] [Related]
4. Enhancing Adoptive Cell Therapy by T Cell Loading of SHP2 Inhibitor Nanocrystals before Infusion.
Li X; Halldórsdóttir HR; Weller S; Colliander A; Bak M; Kempen P; Clergeaud G; Andresen TL
ACS Nano; 2022 Jul; 16(7):10918-10930. PubMed ID: 35838499
[TBL] [Abstract][Full Text] [Related]
5. Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099.
Tani H; Kurita S; Miyamoto R; Ochiai K; Tamura K; Bonkobara M
Vet Comp Oncol; 2020 Jun; 18(2):161-168. PubMed ID: 31339650
[TBL] [Abstract][Full Text] [Related]
6. Allosteric inhibition reveals SHP2-mediated tumor immunosuppression in colon cancer by single-cell transcriptomics.
Gao J; Wu Z; Zhao M; Zhang R; Li M; Sun D; Cheng H; Qi X; Shen Y; Xu Q; Chen H; Chen D; Sun Y
Acta Pharm Sin B; 2022 Jan; 12(1):149-166. PubMed ID: 35127377
[TBL] [Abstract][Full Text] [Related]
7. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M
Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712
[No Abstract] [Full Text] [Related]
8. Allosteric SHP2 inhibition enhances regorafenib's effectiveness in colorectal cancer treatment.
Han X; Wang W; Wang R; Zhang W; Zhu L; Xu Q; Guo W; Gu Y
Biochem Biophys Res Commun; 2024 May; 709():149812. PubMed ID: 38564942
[TBL] [Abstract][Full Text] [Related]
9. Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2
Du S; Lu XH; Li WY; Li LP; Ma YC; Zhou L; Wu JW; Ma Y; Wang RL
Mol Divers; 2021 Aug; 25(3):1873-1887. PubMed ID: 33392964
[TBL] [Abstract][Full Text] [Related]
10. Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment.
Quintana E; Schulze CJ; Myers DR; Choy TJ; Mordec K; Wildes D; Shifrin NT; Belwafa A; Koltun ES; Gill AL; Singh M; Kelsey S; Goldsmith MA; Nichols R; Smith JAM
Cancer Res; 2020 Jul; 80(13):2889-2902. PubMed ID: 32350067
[TBL] [Abstract][Full Text] [Related]
11. SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms.
Wang Y; Mohseni M; Grauel A; Diez JE; Guan W; Liang S; Choi JE; Pu M; Chen D; Laszewski T; Schwartz S; Gu J; Mansur L; Burks T; Brodeur L; Velazquez R; Kovats S; Pant B; Buruzula G; Deng E; Chen JT; Sari-Sarraf F; Dornelas C; Varadarajan M; Yu H; Liu C; Lim J; Hao HX; Jiang X; Malamas A; LaMarche MJ; Geyer FC; McLaughlin M; Costa C; Wagner J; Ruddy D; Jayaraman P; Kirkpatrick ND; Zhang P; Iartchouk O; Aardalen K; Cremasco V; Dranoff G; Engelman JA; Silver S; Wang H; Hastings WD; Goldoni S
Sci Rep; 2021 Jan; 11(1):1399. PubMed ID: 33446805
[TBL] [Abstract][Full Text] [Related]
12. Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.
Garcia Fortanet J; Chen CH; Chen YN; Chen Z; Deng Z; Firestone B; Fekkes P; Fodor M; Fortin PD; Fridrich C; Grunenfelder D; Ho S; Kang ZB; Karki R; Kato M; Keen N; LaBonte LR; Larrow J; Lenoir F; Liu G; Liu S; Lombardo F; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Ramsey T; Sellers WR; Shultz MD; Stams T; Towler C; Wang P; Williams SL; Zhang JH; LaMarche MJ
J Med Chem; 2016 Sep; 59(17):7773-82. PubMed ID: 27347692
[TBL] [Abstract][Full Text] [Related]
13. Controlled delivery of a protein tyrosine phosphatase inhibitor, SHP099, using cyclodextrin-mediated host-guest interactions in polyelectrolyte multilayer films for cancer therapy.
Wang S; Battigelli A; Alkekhia D; Fairman A; Antoci V; Yang W; Moore D; Shukla A
RSC Adv; 2020 May; 10(34):20073-20082. PubMed ID: 35520441
[TBL] [Abstract][Full Text] [Related]
14. Targeting SHP2 reverses BRAF inhibitor tolerance in anaplastic thyroid carcinoma.
Tang T; Zhou J; Zhang LX; Yang G; Li WN; Zhu JJ; Xiong YF; Li JD
Anticancer Agents Med Chem; 2023 Feb; ():. PubMed ID: 36786145
[TBL] [Abstract][Full Text] [Related]
15. Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition.
LaRochelle JR; Fodor M; Vemulapalli V; Mohseni M; Wang P; Stams T; LaMarche MJ; Chopra R; Acker MG; Blacklow SC
Nat Commun; 2018 Oct; 9(1):4508. PubMed ID: 30375388
[TBL] [Abstract][Full Text] [Related]
16. SHP2 allosteric inhibitor TK-453 alleviates psoriasis-like skin inflammation in mice via inhibition of IL-23/Th17 axis.
Wang M; Li T; Ouyang Z; Tang K; Zhu Y; Song C; Sun H; Yu B; Ji X; Sun Y
iScience; 2022 Apr; 25(4):104009. PubMed ID: 35310939
[TBL] [Abstract][Full Text] [Related]
17. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
18. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
20. Dual Allosteric Inhibition of SHP2 Phosphatase.
Fodor M; Price E; Wang P; Lu H; Argintaru A; Chen Z; Glick M; Hao HX; Kato M; Koenig R; LaRochelle JR; Liu G; McNeill E; Majumdar D; Nishiguchi GA; Perez LB; Paris G; Quinn CM; Ramsey T; Sendzik M; Shultz MD; Williams SL; Stams T; Blacklow SC; Acker MG; LaMarche MJ
ACS Chem Biol; 2018 Mar; 13(3):647-656. PubMed ID: 29304282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
